Creatine may enhance the body’s ability to fight cancer by energizing dendritic cells, which are critical for activating killer T cells. A study from UCLA published in iScience demonstrates that creatine supplementation slowed tumor growth in mouse models of melanoma and improved the activation of human immune cells in laboratory settings.
How Creatine Influences Dendritic Cell Activity
Creatine is primarily known as a performance supplement for athletes, but UCLA researchers found it plays a metabolic role in the immune response. According to the study, dendritic cells—specialized cells that detect tumors—rely on a specific creatine transporter protein to function. The research team observed that this transporter gene was significantly more active in dendritic cells that had infiltrated tumors in mice compared to those in healthy tissue.
When researchers engineered dendritic cells to lack this transporter, the cells became less active and struggled to survive. These creatine-deficient cells failed to effectively prepare killer T cells to recognize and attack tumors. In lab experiments, T cells paired with these deficient dendritic cells multiplied less and produced fewer of the signaling molecules required for a robust anti-cancer response.
Impact on Tumor Growth and ATP Levels
The UCLA team tested whether increasing creatine levels could reverse these deficiencies. In mouse models of melanoma, daily creatine injections significantly slowed the growth of tumors. The researchers reported an increase in both the number and the activity of dendritic cells entering the tumors, which subsequently released more chemical signals to attract other immune cells to the site.
The mechanism behind this improvement is linked to cellular energy. Using metabolomics analyses, the scientists found that creatine supplementation increased intracellular ATP (adenosine triphosphate) levels within the dendritic cells. ATP is the primary energy currency for nearly all cellular processes. By boosting these reserves, creatine allowed dendritic cells to maintain the inflammatory signaling pathways needed for activation, even while competing with fast-growing tumor cells for limited nutrients.
Potential Applications for Cancer Vaccines and Immunotherapy
Current cancer immunotherapies aim to activate killer T cells, but they only provide meaningful benefits to approximately 20% to 40% of patients. Lili Yang, the study’s senior author and a professor at UCLA, stated that creatine doesn’t just help the T cells themselves, but energizes the entire infrastructure that supports and guides them.
The research also extended to human immune cells. In laboratory tests, creatine enhanced the activation of human monocyte-derived dendritic cells. Because these cells are frequently used to develop dendritic cell cancer vaccines, the findings suggest that adding creatine during the production of these vaccines could improve their efficacy. James Elsten-Brown, a co-first author of the study, noted that creatine could serve as a supplement for patients already receiving immunotherapy or as a tool to improve vaccine quality before administration.
Clinical Limitations and Safety Warnings
While the results are promising, the researchers emphasize that these findings are based on mice and human cells grown in a lab, not on human cancer patients. This research does not currently serve as evidence that taking creatine supplements will improve cancer treatment outcomes in people.
The experimental approaches used in the study haven’t been approved by the FDA for use in humans. Although creatine monohydrate is generally considered safe at recommended doses, the UCLA team stresses that any patient undergoing cancer treatment must consult their physician before starting any new supplement routine.
Summary of Research Findings
| Focus Area | Observed Effect of Creatine | Biological Result |
|---|---|---|
| Dendritic Cells | Increased ATP levels | Higher survival and activation rates |
| Tumor Growth | Daily injections (mice) | Significant slowing of melanoma growth |
| T Cell Response | Enhanced coordination | Increased multiplication and signaling |
| Vaccine Potential | Lab-grown human cells | Improved stimulation of T cells against targets |
The next phase of research will involve prospective clinical trials to determine if creatine supplementation can realistically improve outcomes for human patients undergoing cancer immunotherapy.